Number experiencing adverse effects · adults with migraine
It is very uncertain whether botulinum toxin type A changes total number of participants experiencing an adverse event compared with other established prophylactic agent (very low certainty).
1 finding from 1 review
Number of migraine days per month: chronic migraine only · adults with migraine
1 finding from 1 review
Headache (frequency) · adults with migraine
1 finding from 1 review
Headache (frequency) · people with episodic migraine
2 findings from 1 review
Response · people with episodic migraine
Acupuncture probably leads to higher response compared with prophylactic drugs (moderate certainty).
2 findings from 1 review
Adverse effects (drop‐outs due to adverse effects4) · people with episodic migraine
Acupuncture probably leads to lower number of participants dropping out due to adverse effects compared with prophylactic drugs (moderate certainty).
1 finding from 1 review
Number of participants reporting an adverse event · people with episodic migraine
Acupuncture probably leads to lower number of participants reporting adverse effects compared with prophylactic drugs (moderate certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with different dose of the same anticoagulant (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with different dose of the same anticoagulant (low certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in venous thromboembolism compared with antiplatelet agent (low certainty).
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with antiplatelet agent (low certainty).
1 finding from 1 review